title: Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD.
authors.affiliation: Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA.
authors.forename: Charles C
authors.initials: CC
authors.lastname: Wykoff
authors.forename: David M
authors.initials: DM
authors.lastname: Brown
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Croft
authors.forename: Tien P
authors.initials: TP
authors.lastname: Wong
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab